Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2020

Conditions
Leukemia
Interventions
DRUG

Rituximab

375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.

DRUG

Urelumab

8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER